Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuron (IMRN) Cash & Equivalents (2017 - 2025)

Immuron (IMRN) has 9 years of Cash & Equivalents data on record, last reported at $1.8 million in Q2 2025.

  • For Q2 2025, Cash & Equivalents fell 76.4% year-over-year to $1.8 million; the TTM value through Jun 2025 reached $1.8 million, down 76.4%, while the annual FY2025 figure was $1.8 million, 76.0% down from the prior year.
  • Cash & Equivalents reached $1.8 million in Q2 2025 per IMRN's latest filing, down from $7.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $19.3 million in Q2 2021 and bottomed at $1.8 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $11.2 million, with a median of $11.5 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 805.35% in 2021, then plummeted 76.4% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $19.3 million in 2021, then dropped by 17.89% to $15.8 million in 2022, then dropped by 27.58% to $11.5 million in 2023, then plummeted by 33.01% to $7.7 million in 2024, then tumbled by 76.4% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $1.8 million in Q2 2025, $7.7 million in Q2 2024, and $11.5 million in Q2 2023.